Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis
Wun T, Telen M, Krishnamurti L, McCavit T, DeCastro L, Flanner H, Kuypers F, Larkin S, Rhee S, Magnani J, Thackray H. Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis. Blood 2014, 124: 2704. DOI: 10.1182/blood.v124.21.2704.2704.Peer-Reviewed Original ResearchSoluble E-selectin levelsPhase 2 trialVaso-occlusive crisisSE-selE-selectin levelsClinical outcomesAdhesion molecule-1Placebo groupLast doseSubgroup analysisE-selectinMolecule-1Sickle cell disease vaso-occlusive crisisDouble-blind phase 2 trialSoluble adhesion molecules E-selectinBaseline white blood cell countRandomized phase 2 studySCD vaso-occlusive crisisSoluble adhesion molecule concentrationsAge groupsVascular cell adhesion molecule-1White blood cell countIntercellular adhesion molecule-1Adhesion molecules E-selectinCell adhesion molecule-1